Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Article content
Article content
Patent-protected aminated tryptamine derivatives strengthen Enveric's leadership in next-generation mental health treatments
Article content
CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering compositions of matter and methods of use for a novel class of aminated tryptamine derivatives.
Article content
The patented compounds were designed through Enveric's proprietary discovery platform and represent a first-in-class approach to non-hallucinogenic psychedelic-inspired therapeutics. The compounds demonstrated low hallucinogenic liability in preclinical testing, including minimal Head Twitch Response (HTR) and reduced 5-HT2A receptor activation – two established indicators of hallucinogenic activity in rodents.
Article content
'The allowance of this application adds a new tier of patent-protected innovation to our pipeline of non-hallucinogenic neuroplastogens,' said Joseph Tucker, Ph.D., CEO of Enveric. 'Unlike traditional psychedelics that require intensive clinical monitoring due to their hallucinogenic effects, our molecules are designed for frequent, flexible, outpatient dosing, which we expect will be better aligned with patient lifestyles, clinics workflows, and payers established models.'
Article content
Non-hallucinogenic psychedelic analogs represent a critical evolution in the treatment of psychiatric and neurological disorders, with potential to treat conditions like depression, anxiety, PTSD, and cognitive impairment, without the operational limitations of hallucinatory experiences. The patent covers both the molecular compositions and their therapeutic applications, further strengthening Enveric's competitive position in this emerging category.
Article content
'This achievement reflects Enveric's continued execution on its mission to develop safe and effective neuroplastogenic therapeutics,' Dr. Tucker added. 'Each addition to our intellectual property portfolio helps build a more valuable portfolio of assets for long-term growth.'
Article content
The patented molecules were discovered through the Company's proprietary discovery and development platform, which leverages computational and medicinal chemistry to identify optimized, next-generation therapeutic molecules with favorable safety, pharmacology, and scalability profiles.
Article content
About Enveric Biosciences
Article content
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders. Leveraging its unique discovery and development Psybrary™ platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ platform drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com.
Article content
Forward-Looking Statements
Article content
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.
Article content
A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Article content
Article content
Article content
Article content
Contacts

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Globe and Mail

9 minutes ago

• Globe and Mail

10 Stock Splits Investors Could See Happen by 2026

Few things garner attention for a stock as much as a stock split. Though a split does nothing to change the fundamentals of a stock or the business, it excites investors for a number of reasons. First, they're the primary tool by which companies can artificially lower their share prices, thereby making them more affordable to individual investors. Second, they act as a milestone for the stock, essentially resetting its growth path so it can rise again. Third, management chooses the timing of stock splits, and they generally signal confidence from management that the stock can keep going up. If management was not confident about the stock's ability to keep gaining, they would be less likely to issue a stock split. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Finally, there's also evidence that stock-split stocks outperform the S&P 500 over the 12 months following the split, according to research from Bank of America. While that's not a reason to buy stock-split stocks, it is a reason to pay attention to them. On that note, let's take a look at 10 stocks that could split by the end of 2026. 1. AutoZone AutoZone's (NYSE: AZO) chief rival, O'Reilly Automotive, just issued a 15-for-1 stock split, and AutoZone looks like a great candidate for one next year as well. The seller of aftermarket auto parts now trades north of $3,600 per share, making it one of the highest share prices on the stock market. AutoZone has a long track record of growth and performing well in both bull and bear markets. After tripling over the last five years, the stock seems overdue for a stock split. 2. MercadoLibre MercadoLibre (NASDAQ: MELI) is another longtime successful now trading at a lofty share price of around $2,500. The stock is up more than 8,000% since its 2009 IPO but has never had a stock split in its history. The company continues to grow rapidly thanks to its strong positioning in e-commerce and digital payments in fintech, meaning a stock split makes sense at some point, if not by the end of next year. 3. Costco Costco Wholesale (NASDAQ: COST) is a unique retailer in a number of ways, and that includes its approach to its share price, which is now hovering around $1,000, well above any mass market retailer. Costco has not done a stock split since 2000, but considering the high share price of the stock and the overall health of the business, a stock split would likely be greeted warmly by investors, especially for retail investors who just have a little cash to spend. 4. ASML ASML (NASDAQ: ASML) is one of the leading semiconductor equipment companies in the world. In fact, it's the only maker of extreme ultraviolet (EUV) lithography equipment used to make the most advanced chips for AI and other applications. ASML's stock price is currently trading around $800, making it a good candidate for a stock split as it has not done so since 2012, when it did an unusual reverse 77-for-100 stock split. 5. Coinbase Crypto is having a big year with Bitcoin hitting an all-time high, legislation regulating stablecoins passing, and the post-IPO of Circle, the owner of the stablecoin USDC. Against that backdrop, it wouldn't be a surprise to see Coinbase (NASDAQ: COIN) split its stock. Its share price is currently around $300. That isn't especially high, but the stock would likely soar on a stock-split announcement, so doing one to take advantage of the tailwinds in crypto could make sense. 6. Booking Holdings With a share price above $5,000, Booking Holdings (NASDAQ: BKNG) may be one of the most obvious candidates for a stock split. However, the online travel agency has thus far resisted it. The company has only ever done a 1-for-6 reverse stock split when it was at its nadir in 2003 following the dot-com bust. Management may be opposed to a stock split, but doing so would likely make the stock more available to more investors. 7. Netflix Netflix (NASDAQ: NFLX) has been one of the biggest surprises over the last three years as the company overcame a decline in subscribers in 2022 and has since surged with the help of its new advertising tier, a crackdown on password sharing, and a push into live TV. With its share price now above $1,000, a stock split wouldn't be a surprise, especially since the company has done them several times in its history. 8. ServiceNow ServiceNow (NYSE: NOW) is one of the most successful software-as-a-service stocks, and it's now one of the highest-priced at nearly $1,000 a share. The company continues to invest in new AI features and deliver steady growth. The company has never done a stock split since going public in 2012. 9. Meta Platforms Meta Platforms (NASDAQ: META) is the only member of the "Magnificent Seven" to have never done a stock split. After going public in 2012, the stock has risen nearly 2,000% to around $700 a share. It's unclear if Meta will do a stock split by 2026, but one seems likely if the stock keeps climbing. 10. Intuit Finally, Intuit (NASDAQ: INTU) looks like a good prospect for a stock split. Shares of the owner of TurboTax and QuickBooks are trading at around $750 a share, and the stock has been a strong performer for years, recently benefiting from advances in AI to make its products easier to use. The company's most recent stock split came in 2006 so it seems due for another one. Should you invest $1,000 in Costco Wholesale right now? Before you buy stock in Costco Wholesale, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Costco Wholesale wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Bank of America is an advertising partner of Motley Fool Money. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Jeremy Bowman has positions in ASML, Bank of America, MercadoLibre, Meta Platforms, and Netflix. The Motley Fool has positions in and recommends ASML, Bank of America, Bitcoin, Booking Holdings, Costco Wholesale, Intuit, MercadoLibre, Meta Platforms, and Netflix. The Motley Fool recommends Coinbase Global. The Motley Fool has a disclosure policy.

CTV News

an hour ago

• CTV News

Pricey TikTok skin care routines for kids raise alarms in new study

Children as young as seven are making TikTok videos about their meticulous and pricey skin care routines. Known as 'Sephora Kids,' they are the focus of a new study that raises alarms about the trend. 'We found that the skin care routines posted by creators aged 18 and under were complicated, costly, and time consuming,' lead author and dermatologist Dr. Molly Hales told 'The skin care routines offered few benefits to the young people that they were targeting, and they carried risks of irritation, skin allergy, and sun sensitivity.' Hales is a postdoctoral research fellow at Northwestern University's medical school in Chicago. For the study, Hales and another researcher created new TikTok accounts posing as 13-year-olds. They analyzed 100 skin care videos by content creators ages 7 to 18, and recorded the number and types of products that were used, as well as the total cost of each skin care regimen. On average, the content creators used six products per video. The average cost of the products used in each regimen was US$168 while the most expensive exceeded $500. The videos the researchers analyzed had an average of 1.1 million views. The 25 most-viewed videos featured products with an average of 11, and a maximum of 21, ingredients that could potentially lead to skin irritation, sun sensitivity or skin allergy. 'We found significant dermatologic risks associated with these regimens, including a very high risk of irritation,' Hales added in a news release from Northwestern University. 'That high risk of irritation came from both using multiple active ingredients at the same time, such as hydroxy acids, as well as applying the same active ingredient unknowingly over and over again when that active ingredient was found in three, four, five different products.' Only a quarter (26.2 per cent) of daytime skin regimens included sunscreen, which Hales says is an incredibly important product for young and old skin alike. 'It's really the only product that is recommended in this age group for those who don't have a known skin condition such as acne or eczema,' Hales told 'It's particularly important given that we found in our study that the most popular active ingredients in these youth skin care routines are alpha hydroxy acids, which are known to increase sun sensitivity.' In one video, a content creator applied 10 products to her face in six minutes – and quickly regretted it. 'You can see that she's turning bright red,' Hales said. 'She wraps up the video by saying, 'If anyone knows how to get it to stop burning, that would be greatly appreciated because it actually hurts a lot.'' Senior author and pharmacist Dr. Tara Lagu also noted potential harms that went beyond just product ingredients. 'We saw that there was preferential, encoded racial language in some cases that really emphasized lighter, brighter skin,'Lagu, an adjunct lecturer at Northwestern University, said in the news release. 'I think there also were real associations between use of these regimens and consumerism.' Lagu got the idea for the study after asking her 12-year-old niece what she wanted for Christmas and getting a list of $300 worth of skin care products. 'After digging around a bit, she realized that nobody had done a formal study of the skin care routines that were circulating among teens and pre-teens on social media,' Hales told 'She approached me about a potential collaboration, knowing that I'm both a dermatologist and a medical anthropologist with a background in digital and social media.' Published in the American Academy of Pediatrics, it is the first peer-reviewed study of its kind. The study's authors conclude that the videos offer little to no benefit for their young audience. They also note that it can hard for parents to track what their children are viewing on TikTok because of age-based algorithms. 'I would encourage parents to make sure that their kids understand that they don't need to be using tons of costly products in order to have healthy skin, or to take care of themselves and their skin,'Hales told 'These skin care videos can be fun and playful, and given their popularity, they likely aren't going away anytime soon. But it's troubling when this content sets an unrealistic standard of beauty and then promotes it in the name of 'health.'' Dr. Elena Hope, the head of pediatric dermatology at SickKids hospital in Toronto, was not involved in the study but echoed its recommendations. She said children should avoid using products with fragrances, essential oils and retinoids, urging parents to educate themselves about potentially harmful ingredients. 'Daily moisturizers that have been tested for tolerability and sunscreens are the only recommendations we have for children,' Hope said in an email to 'All other preparations are not needed and may be harmful.'

National Post

3 hours ago

• National Post

Daily Horoscope - Sunday, June 22, 2025

Moon Alert Avoid shopping or major decisions from 9:30 PM to 11:15 PM EDT today (6:30 PM to 8:15 PM PDT). After that, the Moon moves from Taurus into Gemini. Article content The Stars Rate Your Day 5-Dynamic; 4-Positive; 3-Average; 2-So-so; 1-Difficult Article content Article content Aries (March 21-April 19) *** You can get a lot done today because you feel positive and enthusiastic about what you're doing. Real-estate opportunities along with anything related to your job, your health, or a pet will be worthwhile exploring. Whatever begins now will probably turn out well. Article content Taurus (April 20-May 20) **** You feel confident today, especially about financial speculation or risky ventures. (You feel blessed by Lady Luck.) Enjoy shopping for wardrobe items for yourself. Likewise, social outings, sports events and fun times with children will be rewarding. Article content Gemini (May 21-June 20) **** An effort to improve where you live will go well today. Some of you might also entertain or have a group to your home for a specific reason. This is because all kinds of collaborative activity related to home and family will be positive. In fact, this could be the beginning of something successful! Article content Cancer (June 21-July 22) ***** Everything is in your favour today because you're effective in all your communications with others. Not only will you be forthright and direct, you'll also be warm hearted and inspirational. You can be the Pied Piper if you want to set your army marching. Article content Leo (July 23-Aug. 22) **** Trust in your ability to do something to boost your income today. You might even 'feel' richer because you will purchase something that makes you feel special. Listen to your moneymaking ideas. Whatever you initiate today could grow into something that is successful in the future. Article content Virgo (Aug. 23-Sept. 22) **** This is an excellent day for business and commercial ventures. For starters, your objectives and goals are clearer to you than usual, and this enables you to deal intelligently with others. The result of this is you can get the best deal possible for yourself. Article content Libra (Sept. 23-Oct. 22) **** Some ideas that might be percolating in the back of your head or perhaps some kind of private, behind-the-scenes activity could ultimately boost your reputation, and your career in a successful way. Trust your instincts. Whatever you do now can bring opportunities for personal growth. Article content Scorpio (Oct. 23-Nov. 21) **** Your success in dealing with friends and groups today could lead to future travel opportunities or a chance to deal favourably, especially with legal matters. Be patient. See what develops. Nevertheless, expect successful results. Accept the help of others. Article content Sagittarius (Nov. 22-Dec. 21) **** This is a powerful day for you because fiery Mars is at the top of your chart dancing beautifully with your ruler lucky Jupiter. This influence could bring money or practical help to you from others, especially partners. This might be an inheritance, or financial favours, or practical help. Article content Capricorn (Dec. 22-Jan. 19) **** Act on any travel plans you have today because this is the day to set things in motion. This could be travel for pleasure. Or it might be related to family matters, a friend, spouse or your job. Meanwhile, legal and medical issues will improve. Article content Aquarius (Jan. 20-Feb. 18) **** Work-related travel will be successful for many of you today. Others might see ways to expand, perhaps with connections with other countries. This is a good time to either improve your existing job, or look for a better one because everything is in your favour. Article content Pisces (Feb. 19-March 20) **** Today your physical energy is high, which means you are probably enjoying good health and good spirits. Business and commercial ventures are blessed. Relations with partners and close friends will be positive because you're full of buoyant optimism for your future plans. (And we both know that enthusiasm is contagious!) Article content